Patient	Demographics	Age (years)	Gender	Race W = white B = black O = other	Past medical history HTN = Hypertension HLD = Hyperlipidemia DM = Diabetes Mellitus CKD = Chronic Kidney Disease ESRD = End-Stage Renal Disease Hx of PC I= History of percutaneous coronary intervention
1		67	F	B	Heart failure with reduced ejection fraction
2		38	M	B	HTN, HLD, ESRD
3		71	M	B	DM, HTN, HLD
4		73	F	B	HTN, HLD, Hx of PCI
5		60	M	O	None documented
6		63	M	W	None documented
7		57	M	W	DM, HTN, HLD, CKD
8		65	M	B	DM, HTN, HLD, ESRD
9		68	M	W	HTN
10		52	M	O	DM, HTN, HLD, ESRD, Hx of PCI
11		77	F	B	DM, HTN, HLD, CKD, Hx of PCI
12		48	M	B	DM, HTN
13		51	M	W	HTN
14		58	F	W	DM, HTN, CKD
15		51	F	B	None documented

Patient	Current smoker	Hospitalization outcomes	Length of stay (days)	ICU level care required	Intubation required (days)
1	Y		26	Y	N
2	N		8	N	N
3	N		33	Y	Y (33)
4	N		2	N	N
5	N		11	N	N
6	N		6	N	N
7	N		6	N	N
8	N		54	Y	Y (31)
9	N		25	Y	Y (16)
10	N		8	Y	N
11	Y		4	N	N
12	N		15	Y	N
13	N		11	Y	N
14	N		2	N	N
15	N		6	N	N

Patient	COVID treatment therapies delivered	MPI study	Inpatient (I) vs outpatient (O)	Indication for study	Exercise (E) vs phamacologic (P) (regadenoson)
1	10 days dexamethasone + 5 days remdesivir		I	Heart failure evaluation	P
2	Supportive care		O	Pre-operative evaluation for kidney transplant	P
3	10 days dexamethasone		O	Non-sustained ventricular tachycardia	P
4	Supportive care		O	Shortness of breath	E
5	Enrolled in blinded remdesivir trial		O	Chest pain	E
6	10 days dexamethasone + 5 days remdesivir		I	Chest pain	E
7	5 days dexamethasone + enrolled in canakinumab trial		O	Chest pain	E
8	1 day remdesivir, 1 unit of convalescent plasma		O	Shortness of breath	P
9	10 days dexamethasone + 10 days remdesivir		O	Heart failure evaluation	P
10	Supportive care		O	Pre-operative evaluation for kidney transplant	P
11	Supportive care		I	Chest pain	P
12	5 days dexamethasone + 5 days remdesivir		I	Shortness of breath	P
13	10 days dexamethasone + 5 days remdesivir		O	Chest pain	P
14	Supportive care		O	Chest pain	P
15	Supportive care		I	Chest pain	P

Patient	Symptoms during MPI study	Other notes	Days between first positive COVID-19 test and MPI study	Days between COVID-related hospitalization discharge and MPI study
1	Dyspnea, abdominal cramping		24	n/a
2	Dyspnea		171	164
3	None		59	24
4	Fatigue		94	93
5	Dyspnea, fatigue		191	188
6	Fatigue, shortness of breath, chest pain		34	25
7	Dyspnea, fatigue		65	60
8	None		96	70
9	None		79	55
10	Dyspnea		86	78
11	Dyspnea, headache		62	58
12	Dyspnea		22	n/a
13	Dyspnea		88	74
14	Chest pain	Aminophylline administered for chest pain	31	30
15	Palpitations		22	17